Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the adult AIDS clinical trial group cardiovascular disease focus group

Kenneth H. Mayer, Michael P. Dubé, Dennis Sprecher, W. Keith Henry, Judith A. Aberg, Francesca J. Torriani, Howard N. Hodis, Jeffrey Schouten, Jules Levin, Gary Myers, Robert Zackin, Thomas Nevin, Judith S. Currier

Research output: Contribution to journalArticlepeer-review

205 Scopus citations

Abstract

Dyslipidemia is a prevalent condition that affects patients infected with human immunodeficiency virus (HIV) who are receiving antiretroviral therapy. These preliminary recommendations summarize the current understanding in this area and propose guidelines for management. Existing guidelines for the management of dyslipidemia in the general population formed the general basis for our recommendations. Data on the prevalence and treatment of dyslipidemia of HIV-infected patients, implications of treatment-related dyslipidemia in other chronically ill populations, and pharmacokinetic profiles for the available hypolipidemic agents in non-HIV populations were considered. Although the implications of dyslipidemia in this population are not fully known, the frequency, type, and magnitude of lipid alterations in HIV-infected people are expected to result in increased cardiovascular morbidity. We propose that these patients undergo evaluation and treatment on the basis of existing guidelines for dyslipidemia, with the caveat that avoidance of interactions with antiretroviral agents is paramount.

Original languageEnglish (US)
Pages (from-to)1216-1224
Number of pages9
JournalClinical Infectious Diseases
Volume31
Issue number5
DOIs
StatePublished - 2000

Fingerprint

Dive into the research topics of 'Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the adult AIDS clinical trial group cardiovascular disease focus group'. Together they form a unique fingerprint.

Cite this